Dzierżyńska Maria, Sawicka Justyna, Łada Katarzyna, Gajewicz-Skretna Agnieszka, Deptuła Milena, Chernobrovkin Alexey, Pogorzelska Aneta, Grubb Anders, Zubarev Roman A, Pikuła Michał, Kasprzykowski Franciszek, Rodziewicz-Motowidło Sylwia
Department of Biomedical Chemistry, Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdansk, Poland.
Department of Molecular Biotechnology, Mossakowski Medical Research Institute Polish Academy of Science, Wita Stwosza 63, 80-308 Gdansk, Poland.
ACS Omega. 2025 Jul 22;10(30):33435-33460. doi: 10.1021/acsomega.5c03775. eCollection 2025 Aug 5.
The emergence of drug-resistant Gram-positive pathogens, particularlyand, has driven the need for novel antimicrobial agents. This study explores 21 newly synthesized peptidomimetic analogues of cystatin C -terminal fragment, designed to enhance bioactivity, solubility, and safety. These compounds were evaluated for antimicrobial potency, cytotoxicity, pro-proliferative effects, and pharmacokinetic properties. Key findings indicate that analogues A-192 and A-164 exhibited the strongest antimicrobial effects against and . Most compounds were inactive against Gram-negative bacteria. Cytotoxicity profiling identified several derivatives with low to moderate toxicity and favorable pro-proliferative effects at specific concentrations. Stability tests confirmed the robustness in aqueous and plasma environments. Computational absorption, distribution, metabolism, excretion, and toxicity (ADMET) modeling revealed low gastrointestinal absorption, but favorable parameters for topical applications. Exploratory analyses (principal component analysis (PCA) and two-way hierarchical cluster analysis (2D-HCA)) linked structural featuressuch as branching, molecular weight, and solubility, with biological activity. These results support the potential of structurally optimized peptidomimetics as targeted, topical therapeutics for Gram-positive infections and provide a rationale for further preclinical development.
耐多药革兰氏阳性病原体的出现,尤其是[病原体名称缺失],推动了对新型抗菌药物的需求。本研究探索了21种新合成的胱抑素C末端片段的拟肽类似物,旨在增强生物活性、溶解性和安全性。对这些化合物进行了抗菌效力、细胞毒性、促增殖作用和药代动力学特性评估。主要研究结果表明,类似物A - 192和A - 164对[病原体名称缺失]表现出最强的抗菌作用。大多数化合物对革兰氏阴性菌无活性。细胞毒性分析确定了几种在特定浓度下具有低至中度毒性且具有良好促增殖作用的衍生物。稳定性测试证实了其在水性和血浆环境中的稳定性。计算吸收、分布、代谢、排泄和毒性(ADMET)模型显示胃肠道吸收低,但局部应用的参数良好。探索性分析(主成分分析(PCA)和双向层次聚类分析(2D - HCA))将结构特征(如支化、分子量和溶解度)与生物活性联系起来。这些结果支持了结构优化的拟肽作为针对革兰氏阳性感染的靶向局部治疗药物的潜力,并为进一步的临床前开发提供了理论依据。